Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell, C and Ampikaipakan, S and Sexton, DW and Price, D and Freeman, D and Thomas, M and Ali, M and Wilson, AM (2014) Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 9. pp. 715-721. ISSN 1178-2005

[img] Text
Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease..pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (236kB)

Abstract

Purpose: The objective of this pilot trial was to evaluate the safety and efficacy of AKL1, a patented botanical formulation containing extracts of Picrorhiza kurroa, Ginkgo biloba, and Zingiber officinale, as add-on therapy for patients with chronic obstructive pulmonary disease (COPD) and chronic cough.
Patients and methods: This randomized, double-blind, placebo-controlled trial enrolled male and female patients .18 years old with COPD and Leicester Cough Questionnaire (LCQ) score of ,18. The 10-week study period comprised a 2-week single-blind placebo run-in period followed by add-on treatment with AKL1 or placebo twice daily for 8 weeks. The primary study endpoint was the change from week 0 to week 8 in cough-related health status, as assessed by the LCQ.
Results: Of 33 patients enrolled, 20 were randomized to AKL1 and 13 to placebo. Patients included 19 (58%) men and 14 (42%) women of mean (standard deviation [SD]) age of 67 (9.4) years; 15 (45%) patients were smokers and 16 (49%) were ex-smokers. The mean (SD) change from baseline in LCQ score at 8 weeks was 2.3 (4.9) in the AKL1 group and 0.6 (3.7) in the placebo group, with mean difference in change of 1.8 (95% confidence interval: -1.5 to 5.1; P=0.28). The St George’s Respiratory Questionnaire score improved substantially in the AKL1 treatment group by a mean (SD) of -7.7 (11.7) versus worsening in the placebo group (+1.5 [9.3]), with mean difference in change of -9.2 (95% confidence interval: -19.0 to 0.6; P=0.064). There were no significant differences between treatment groups in change from baseline to week 8 in other patient-reported measures, lung function, or the 6-minute walk distance.
Conclusion: Further study is needed with a larger patient population and over a longer duration to better assess the effects of add-on therapy with AKL1 in COPD.

Item Type: Article
Uncontrolled Keywords: 1102 Cardiovascular Medicine And Haematology
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Dove Medical Press Ltd
Related URLs:
Date Deposited: 19 Mar 2015 11:48
Last Modified: 19 Mar 2015 11:48
DOI or Identification number: 10.2147/COPD.S54276
URI: http://researchonline.ljmu.ac.uk/id/eprint/744

Actions (login required)

View Item View Item